Le Lézard
Classified in: Health
Subject: RCL

Urban Remedy Recalls Urban Remedy Organic Revitalizing Tea Tonic - Strawberry Hibiscus Rose Due to Possible Hepatitis A Contamination


RICHMOND, Calif., June 4, 2022 /PRNewswire/ -- Urban Remedy is voluntarily recalling Urban Remedy Organic Revitalizing Tea Tonic Strawberry Hibiscus Rose (LOT 1232 BEST BY 7/17/2022) because it has the potential to be contaminated with Hepatitis A. Urban Remedy contracts Youngstown Grape Distributors Inc. to co-manufacture this product. The product may contain fresh organic strawberries linked to the FDA outbreak investigation of FreshKampo organic strawberries. https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-hepatitis-virus-strawberries-may-2022 .                              

Hepatitis A is a contagious virus that can cause liver disease. A Hepatitis A virus (HAV) infection can range in severity from a mild illness lasting a few weeks to a severe illness lasting several months. In rare cases, particularly consumers who have a pre-existing severe illness or are immune compromised, Hepatitis A infections can progress to liver failure. Illness usually occurs within 15 to 50 days after eating or drinking contaminated food or water. Symptoms of Hepatitis A infection include fever, headache, fatigue, loss of appetite, nausea, vomiting, diarrhea, abdominal pain, jaundice, dark urine or pale stool. In some instances, particularly in children under the age of six, Hepatitis A infection may be asymptomatic.     

Persons who may have purchased the affected product do not consume, if consumed consult your health care provider or local health department to determine if a vaccination is appropriate and consumers with symptoms of Hepatitis A should contact their health providers or the local health department immediately.           

No illnesses have been reported consuming Urban Remedy product to date.

UPC

Description

Lot Number

Product Size

813377025831

Urban Remedy Organic Revitalizing Tea Tonic Strawberry Hibiscus Rose

1232 Best By 7/17/2022

12oz

The product was sold in a 12oz resealable plastic bottle at various retail stores in CA, NM, VA, CO, WA, OR, CO, NY, PA, AZ, IL, OH, MD, WI, TX, WY, MO, ME, KY, MI, NC, MA, NE, and UT states between 5/17/2022 ? 5/29/2022. 

"At Urban Remedy, food safety is our company's top priority," said Paul Coletta, CEO. The company is committed to keeping their consumers informed and is asking those who purchased product with the affected lot number to dispose of the item or return it to place of purchase for full credit. 

Consumers with additional questions can call (855) 875-8423 from 9:00 am to 6:00 pm PDT or email [email protected] 

[email protected]
(855) 875-8423

SOURCE Urban Remedy


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: